Target intelligence / Profile preview

Long intergenic non-protein coding RNA 1977 (LINC01977)

Target
LINC01977
Molecular classification
Long non-coding RNA (lncRNA), Long intergenic non-coding RNA (lincRNA), Other (Non-coding RNA family)
01

Overview

Long intergenic non-protein coding RNA 1977 (LINC01977) is a long non-coding RNA (lncRNA) that does not code for a protein but plays an important regulatory role in gene expression. It is overexpressed in several cancers, including breast, colorectal, hepatocellular, and lung cancer, where it promotes tumor growth, cell migration, invasion, and chemoresistance. LINC01977 acts mainly as a molecular sponge for microRNAs (such as miR-212-3p), modulates the function and stability of proteins (for example, RBM39 and Notch2), and has been implicated as both a prognostic biomarker and a potential therapeutic target in oncology[2][4][6][8]. No currently approved drugs directly target LINC01977, but its influence on chemoresistance (e.g., to doxorubicin) highlights its relevance for future therapeutic development. The clinical utility of LINC01977 as a biomarker or direct target is under active investigation.

Other names
Long intergenic non-protein coding RNA 1977LINC01977
02

Mechanism of action

Molecular sponge/ceRNA: Sequesters specific microRNAs (e.g., miR-212-3p), thus derepressing target mRNAs and promoting oncogenic pathways. Protein binding: Interacts with RNA-binding proteins (e.g., RBM39) affecting protein stability (such as stabilizing Notch2 in liver cancer). Transcriptional and post-transcriptional regulation.

03

Biological functions

Cell proliferationCell migrationCell invasionGene regulation (mainly via acting as a competing endogenous RNA, or molecular sponge, for microRNAs)Regulation of cell cycle (context-dependent)Chemoresistance (notably to doxorubicin in breast cancer)
04

Disease associations

Cancer (including, but not limited to, breast cancer, colorectal cancer, hepatocellular carcinoma, lung cancer)Chemoresistance (particularly in breast and colorectal cancers)Other disease roles are not yet established beyond oncology
05

Safety considerations

Off-target gene regulation: Targeting lncRNAs may have unpredictable downstream consequences due to broad regulatory networks.Limited tissue specificity: Depending on cancer type, LINC01977 may be expressed in various tissues, raising potential non-specific effects.
06

Interacting drugs

Doxorubicin
07

Biomarkers

LINC01977 expression levels: Proposed as a biomarker for prognosis and cancer progression, especially in breast, colorectal, and liver cancersPotential diagnostic discrimination: Shown by ROC analysis for colorectal cancer (AUC 0.966)

Beyond the preview

Go deeper on Long intergenic non-protein coding RNA 1977 (LINC01977).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Long intergenic non-protein coding RNA 1977 (LINC01977).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call